C6
Complement component C6
Also known as: CO6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P13671
- Gene
- C6
- Ensembl
- ENSG00000039537
- Chromosome
- 5
- Canonical length
- 934 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a component of the complement cascade. The encoded protein is part of the membrane attack complex that can be incorporated into the cell membrane and cause cell lysis. Mutations in this gene are associated with complement component-6 deficiency. Transcript variants encoding the same protein have been described.[provided by RefSeq, Nov 2012]
Canonical amino-acid sequenceUniProt
934 residues, UniProt reviewed canonical sequence.
>P13671|C6
1 MARRSVLYFI LLNALINKGQ ACFCDHYAWT QWTSCSKTCN SGTQSRHRQI VVDKYYQENF
61 CEQICSKQET RECNWQRCPI NCLLGDFGPW SDCDPCIEKQ SKVRSVLRPS QFGGQPCTAP
121 LVAFQPCIPS KLCKIEEADC KNKFRCDSGR CIARKLECNG ENDCGDNSDE RDCGRTKAVC
181 TRKYNPIPSV QLMGNGFHFL AGEPRGEVLD NSFTGGICKT VKSSRTSNPY RVPANLENVG
241 FEVQTAEDDL KTDFYKDLTS LGHNENQQGS FSSQGGSSFS VPIFYSSKRS ENINHNSAFK
301 QAIQASHKKD SSFIRIHKVM KVLNFTTKAK DLHLSDVFLK ALNHLPLEYN SALYSRIFDD
361 FGTHYFTSGS LGGVYDLLYQ FSSEELKNSG LTEEEAKHCV RIETKKRVLF AKKTKVEHRC
421 TTNKLSEKHE GSFIQGAEKS ISLIRGGRSE YGAALAWEKG SSGLEEKTFS EWLESVKENP
481 AVIDFELAPI VDLVRNIPCA VTKRNNLRKA LQEYAAKFDP CQCAPCPNNG RPTLSGTECL
541 CVCQSGTYGE NCEKQSPDYK SNAVDGQWGC WSSWSTCDAT YKRSRTRECN NPAPQRGGKR
601 CEGEKRQEED CTFSIMENNG QPCINDDEEM KEVDLPEIEA DSGCPQPVPP ENGFIRNEKQ
661 LYLVGEDVEI SCLTGFETVG YQYFRCLPDG TWRQGDVECQ RTECIKPVVQ EVLTITPFQR
721 LYRIGESIEL TCPKGFVVAG PSRYTCQGNS WTPPISNSLT CEKDTLTKLK GHCQLGQKQS
781 GSECICMSPE EDCSHHSEDL CVFDTDSNDY FTSPACKFLA EKCLNNQQLH FLHIGSCQDG
841 RQLEWGLERT RLSSNSTKKE SCGYDTCYDW EKCSASTSKC VCLLPPQCFK GGNQLYCVKM
901 GSSTSEKTLN ICEVGTIRCA NRKMEILHPG KCLALocalizationUniProt · AlphaFold · HPA
Whether an antibody against C6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 2
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 588 nTPM
Expression across tissuesHPA
Tissue
- liver: 588 nTPM
- heart muscle: 52 nTPM
- fallopian tube: 40 nTPM
- pancreas: 40 nTPM
- adipose tissue: 11 nTPM
- gallbladder: 10 nTPM
Single-cell type
- hepatocytes: 582 nCPM
- fallopian tube ciliated cells: 335 nCPM
- cholangiocytes: 335 nCPM
- pancreatic duct cells: 232 nCPM
- respiratory ciliated cells: 206 nCPM
- leydig cells: 186 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 3.3 nTPM
- choroid plexus: 3 nTPM
- thalamus: 1.6 nTPM
- white matter: 1.3 nTPM
- hypothalamus: 1.2 nTPM
- basal ganglia: 0.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about C6.
Disease | AllUniProt
Conditions C6 is implicated in, by any mechanism.
- Complement component 6 deficiency (C6D) MIM:612446
Disease | GeneticClinVar
64 pathogenic / likely-pathogenic of 627 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Complement component 6 deficiency
- C6-related disorder
- Immunodeficiency due to a late component of complement deficiency
- Inborn genetic diseases
Disease | ImmuneIEDB
Conditions an epitope on C6 was assayed in.
- rheumatoid arthritis B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.88
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- complement activation
- complement activation, classical pathway
- complement activation, GZMK pathway
- in utero embryonic development
- killing of cells of another organism
- positive regulation of activation of membrane attack complex
- positive regulation of angiogenesis
- positive regulation of immune response
- transmembrane transport
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Sushi/SCR/CCP domain
- Thrombospondin type-1 (TSP1) repeat
- Membrane attack complex component/perforin/complement C9
- Low-density lipoprotein (LDL) receptor class A repeat
- Kazal domain
- Factor I / membrane attack complex
- Membrane attack complex component/perforin domain, conserved site
- Membrane attack complex component/perforin (MACPF) domain
- Low-density lipoprotein (LDL) receptor class A, conserved site
- Sushi/SCR/CCP superfamily
- LDL receptor-like superfamily
- Thrombospondin type-1 repeat superfamily
- Complement components C8A/B/C6, EGF-like domain
- Low-density lipoprotein receptor domain class A
- Sushi repeat (SCR repeat)
- Thrombospondin type 1 domain
- MAC/Perforin domain
- Complement components C8A/B/C6, EGF-like domain
- Complement component C6, KAZAL domain
- Complement component C6, KAZAL domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of C6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads C6 as an antibody target. Whether an autoantibody or antibody against C6 could matter depends on whether native C6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
C6 is annotated at the cell surface, where native C6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label C6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...